



May 23, 2016

## **Integra LifeSciences launches Integra® Fin-Lock™ Glenoid for the Titan™ Modular Shoulder System**

PLAINSBORO, N.J., May 23, 2016 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART), a leading global medical technology company, today announced the launch of the Integra® Fin-Lock™ Glenoid. This addition to the Titan™ Modular Shoulder System increases the glenoid offerings to include features intended to help maximize long-term fixation and implant longevity.

Glenoid component loosening and failure has been cited as a leading cause of total shoulder arthroplasty complications and failure. The Fin-Lock Glenoid seeks to address this with design attributes that provide immediate and enduring stability. The prosthesis features a central peg with four fins of increased diameter to help improve pull-out strength, and three peripheral pegs to help provide stability against component rocking. The device is manufactured of highly crosslinked polyethylene, to help provide improved wear characteristics over the life of the implant.

"We're very excited to launch the Fin-Lock system. This is an impressive addition to an already robust portfolio that positions Integra as having one of the premier shoulder arthroplasty portfolios in the market. With this launch, we have a strong foundation for Integra's commitment to developing the best glenoid solutions for surgeons and their patients," said Mark Augusti, President of Integra's Orthopedics & Tissue Technologies division.

The Fin-Lock Glenoid was developed in conjunction with Matthew Ramsey, MD, of the Rothman Institute, and William Geissler, MD, of the University of Mississippi Medical Center.

Dr. Geissler said, "I am very impressed with how Integra continues to grow their already expansive shoulder arthroplasty product line. They continue to innovate with new products that help streamline the procedure for the surgeon and improve outcomes for our patients."

### **About Integra**

Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit [www.integralife.com](http://www.integralife.com).

For additional information on the release of the Titan™ Modular Shoulder System Fin-Lock™ Glenoid, please contact [FinLockGlenoid@integralife.com](mailto:FinLockGlenoid@integralife.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Company

Investors  
Angela Steinway  
609-936-2268  
[angela.steinway@integralife.com](mailto:angela.steinway@integralife.com)

Michael Beaulieu  
609-750-2827  
[michael.beaulieu@integralife.com](mailto:michael.beaulieu@integralife.com)

Media

Gianna Sabella

609-775-8553

gianna.sabella@integralife.com